HBK Sorce Advisory LLC Takes Position in Arrowhead Pharmaceuticals, Inc. $ARWR

HBK Sorce Advisory LLC purchased a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in the 3rd quarter, HoldingsChannel reports. The fund purchased 76,408 shares of the biotechnology company’s stock, valued at approximately $2,823,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Arrowhead Pharmaceuticals by 138.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,785,062 shares of the biotechnology company’s stock valued at $60,962,000 after purchasing an additional 2,774,933 shares during the period. Geode Capital Management LLC grew its holdings in shares of Arrowhead Pharmaceuticals by 1.0% during the second quarter. Geode Capital Management LLC now owns 2,978,505 shares of the biotechnology company’s stock valued at $47,067,000 after buying an additional 28,193 shares in the last quarter. Marshall Wace LLP raised its position in Arrowhead Pharmaceuticals by 3,507.8% during the second quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock valued at $34,065,000 after buying an additional 2,096,238 shares during the period. Norges Bank purchased a new stake in Arrowhead Pharmaceuticals in the 2nd quarter worth about $30,414,000. Finally, Goldman Sachs Group Inc. lifted its stake in Arrowhead Pharmaceuticals by 34.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company’s stock worth $22,189,000 after acquiring an additional 447,456 shares in the last quarter. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, Director Michael S. Perry sold 16,250 shares of the stock in a transaction on Friday, December 5th. The shares were sold at an average price of $61.03, for a total transaction of $991,737.50. Following the transaction, the director directly owned 115,240 shares of the company’s stock, valued at $7,033,097.20. This represents a 12.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Christopher Richard Anzalone sold 12,586 shares of the business’s stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $68.44, for a total value of $861,385.84. Following the completion of the sale, the chief executive officer directly owned 3,805,926 shares of the company’s stock, valued at $260,477,575.44. This represents a 0.33% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 368,736 shares of company stock valued at $23,670,228 in the last three months. 4.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ARWR. Morgan Stanley upped their target price on Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the company an “equal weight” rating in a report on Wednesday, November 26th. The Goldman Sachs Group boosted their price objective on shares of Arrowhead Pharmaceuticals from $27.00 to $48.00 and gave the company a “neutral” rating in a research report on Thursday, November 20th. Royal Bank Of Canada increased their target price on shares of Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an “outperform” rating in a research report on Thursday, December 11th. Chardan Capital reissued a “buy” rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Monday, December 1st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Arrowhead Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $61.89.

Arrowhead Pharmaceuticals Price Performance

Shares of ARWR opened at $70.16 on Monday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 4.86 and a current ratio of 4.86. The firm has a market cap of $9.53 billion, a PE ratio of -876.89 and a beta of 1.28. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $9.57 and a twelve month high of $72.36. The firm’s 50 day moving average price is $51.76 and its 200 day moving average price is $33.19.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.